Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALML3 | P27482 | 6/20 | 0.59 |
| ▸ | MAOA | P21397 | 3/20 | 0.51 |
| ▸ | MAOB | P27338 | 3/20 | 0.51 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.48 |
| ▸ | GRM2 | Q14416 | 3/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL541807 | 1.00 | CALML3 (0.59) | CALML3MAOAMAOBS1PR5GRM2 | |
| SCHEMBL9611100 | 0.89 | GRM2 (0.49) | CALML3S1PR5GRM2 | |
| SCHEMBL17769259 | 0.89 | GRM2 (0.47) | CALML3S1PR5GRM2 | |
| SCHEMBL17769261 | 0.89 | GRM2 (0.47) | CALML3S1PR5GRM2 | |
| SCHEMBL2837784 | 0.89 | GRM2 (0.47) | CALML3S1PR5GRM2 | |
| SCHEMBL3209052 | 0.88 | CALML3 (0.50) | CALML3MAOAMAOBS1PR5GRM2 | |
| SCHEMBL3197109 | 0.88 | CALML3 (0.50) | CALML3MAOAMAOBS1PR5GRM2 | |
| SCHEMBL17769267 | 0.86 | GRM2 (0.47) | CALML3MAOAMAOBS1PR5GRM2 | |
| SCHEMBL17769268 | 0.86 | GRM2 (0.47) | CALML3MAOAMAOBS1PR5GRM2 | |
| SCHEMBL18202919 | 0.85 | GRM2 (0.49) | CALML3S1PR5GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016079757-A2 | NOVEL PROCESSES FOR PREPARING 5-HYDROXYMETHYL-OXAZOLIDIN-2-ONE DERIVATIVES | SYMED LABS LIMITED (IN) | 2016-05-26 | — | — | WO | claimed |
| EP-2374806-B1 | OXAZOLIDINON-QUINOLONE HYBRIDES AND INTERMEDIATES FOR THEIR PREPARATION | MORPHOCHEM AG FÜR KOMBINATORISCHE CHEMIE (DE) | 2016-11-02 | — | — | EP | disclosed |
| WO-2016079757-A2 | NOVEL PROCESSES FOR PREPARING 5-HYDROXYMETHYL-OXAZOLIDIN-2-ONE DERIVATIVES | SYMED LABS LIMITED (IN) | 2016-05-26 | — | — | WO | disclosed |
| WO-2016079757-A2 | NOVEL PROCESSES FOR PREPARING 5-HYDROXYMETHYL-OXAZOLIDIN-2-ONE DERIVATIVES | SYMED LABS LIMITED (IN) | 2016-05-26 | — | — | WO | disclosed |
| US-20150336992-A1 | OXAZOLIDINONE-QUINOLONE HYBRID ANTIBIOTICS | MORPHOCHEM AG FÜR KOMBINATORISCHE CHEMIE (DE) | 2015-11-26 | — | — | US | disclosed |
| US-20150336992-A1 | OXAZOLIDINONE-QUINOLONE HYBRID ANTIBIOTICS | MORPHOCHEM AG FÜR KOMBINATORISCHE CHEMIE (DE) | 2015-11-26 | — | — | US | disclosed |
| US-20150336992-A1 | OXAZOLIDINONE-QUINOLONE HYBRID ANTIBIOTICS | MORPHOCHEM AG FÜR KOMBINATORISCHE CHEMIE (DE) | 2015-11-26 | — | — | US | disclosed |
| US-9133213-B2 | Oxazolidinone-quinolone hybrid antibiotics | Morphochem Aktiengesellschaft für kombinatorische Chemie (DE) | 2015-09-15 | — | — | US | disclosed |
| US-9133213-B2 | Oxazolidinone-quinolone hybrid antibiotics | Morphochem Aktiengesellschaft für kombinatorische Chemie (DE) | 2015-09-15 | — | — | US | disclosed |
| US-9133213-B2 | Oxazolidinone-quinolone hybrid antibiotics | Morphochem Aktiengesellschaft für kombinatorische Chemie (DE) | 2015-09-15 | — | — | US | disclosed |
| US-20070155714-A1 | Use of oxazolidinone-quinoline hybrid antibiotics for the treatment of anthrax and other infections | MORPHOCHEM AKTIENGESELLSCHAFT FUR KOMBINATORISCHE CHEMIE (DE) | 2007-07-05 | — | — | US | disclosed |
| US-20070004769-A1 | Intermediate products for producing oxazolidinone-quinolone hybrids | MORPHOCHEM AKTIEGESELLSCHAFT FUR KOMBINATORISCHE CHEMIE (DE) | 2007-01-04 | — | — | US | disclosed |
| US-20070004769-A1 | Intermediate products for producing oxazolidinone-quinolone hybrids | MORPHOCHEM AKTIEGESELLSCHAFT FUR KOMBINATORISCHE CHEMIE (DE) | 2007-01-04 | — | — | US | disclosed |
| US-20070004769-A1 | Intermediate products for producing oxazolidinone-quinolone hybrids | MORPHOCHEM AKTIEGESELLSCHAFT FUR KOMBINATORISCHE CHEMIE (DE) | 2007-01-04 | — | — | US | disclosed |
| EP-1709044-A2 | OXAZOLIDINONE-QUINOLONE HYBRID ANTIBIOTICS | Morphochem Aktiengesellschaft Für Kombinatorische Chemie (DE) | 2006-10-11 | — | — | EP | disclosed |
| EP-1660489-A1 | INTERMEDIATE PRODUCTS FOR PRODUCING OXAZOLIDINONE-QUINOLONE HYBRIDS | Morphochem Aktiengesellschaft Für Kombinatorische Chemie (DE) | 2006-05-31 | — | — | EP | disclosed |
| EP-1620098-A1 | USE OF OXAZOLIDINONE-QUINOLINE HYBRID ANTIBIOTICS FOR THE TREATMENT OF ANTHRAX AND OTHER INFECTIONS | Morphochem Aktiengesellschaft Für Kombinatorische Chemie (DE) | 2006-02-01 | — | — | EP | disclosed |
| WO-2005058888-A2 | OXAZOLIDINONE-QUINOLONE HYBRID ANTIBIOTICS | Morphochem Aktiengesellschaft für kombinatorische Chemie (DE) | 2005-06-30 | — | — | WO | disclosed |
| WO-2005023801-A1 | INTERMEDIATE PRODUCTS FOR PRODUCING OXAZOLIDINONE-QUINOLONE HYBRIDS | Morphochem Aktiengesellschaft für kombinatorische Chemie (DE) | 2005-03-17 | — | — | WO | disclosed |
| WO-2004096221-A1 | USE OF OXAZOLIDINONE-QUINOLINE HYBRID ANTIBIOTICS FOR THE TREATMENT OF ANTHRAX AND OTHER INFECTIONS | Morphochem Aktiengesellschaft für kombinatorische Chemie (DE) | 2004-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004769-A1 | Intermediate products for producing oxazolidinone-quinolone hybrids | OXA1L, NQO1, NQO2 | CALML3 4334/4885MAOA 590/4885MAOB 391/4885 |
| US-20150336992-A1 | OXAZOLIDINONE-QUINOLONE HYBRID ANTIBIOTICS | OXA1L, TOP1, TOP2A | CALML3 3504/4885MAOA 1595/4885MAOB 1428/4885 |
| US-20070155714-A1 | Use of oxazolidinone-quinoline hybrid antibiotics for the treatment of anthrax and other infections | OXA1L, ANTXR2, AAAS | CALML3 2361/4885MAOA 1013/4885MAOB 1111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.